DDrare: Database of Drug Development for Rare Diseases

159. 色素性乾皮症
［臨床試験数：5，薬物数：13（DrugBank：4），標的遺伝子数：4，標的パスウェイ数：13］

Searched query = "Xeroderma pigmentosum", "XP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Ipilimumab; Isotretinoin; Liposomal T4N5 lotion; Nivolumab; Procedure: Biospecimen Collection; TRABECTEDINA; Trabectedina; Trabectedine; YONDELIS 0,25 mg polvo para concentrado para solución para perfusión; YONDELIS 1 mg polvo para concentrado para solución para perfusión; Yondelis; Yondelis 0.25 mg powder for concentrate for solution for infusion.; Yondelis 1 mg powder for concentrate for solution for infusion.

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04500548 (ClinicalTrials.gov)	February 26, 2021	4/8/2020	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers	Constitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma Pigmentosum	Procedure: Biospecimen Collection;Biological: Ipilimumab;Biological: Nivolumab	National Cancer Institute (NCI)	NULL	Not yet recruiting	12 Months	25 Years	All	40	Phase 1	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04500548
(ClinicalTrials.gov)

February 26, 2021

4/8/2020

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers

Constitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma Pigmentosum

Procedure: Biospecimen Collection;Biological: Ipilimumab;Biological: Nivolumab

National Cancer Institute (NCI)

NULL

Not yet recruiting

12 Months

25 Years

All

Phase 1

NULL